Abstract
To describe clinical features and outcomes of 26 patients with idiopathic retroperitoneal fibrosis from a single center, we reviewed medical records of consecutive patients with idiopathic retroperitoneal fibrosis evaluated at our facility from January 1, 1998 to December 31, 2013 for clinical features, laboratory and radiographic findings, management, and outcomes. Twenty-six patients met criteria for idiopathic retroperitoneal fibrosis and were included in the study. Median age at diagnosis was 58 years; male–female ratio was 3.3:1.0. Median duration of symptoms was 7 weeks. Abdominal, flank, and/or low back pain were the most common presenting symptoms. Four patients (15 %) had associated autoimmune or fibrosing disorders. Baseline erythrocyte sedimentation rate was elevated in 17 (77 %) of 22 patients tested and C-reactive protein was elevated in 10 (56 %) of 18 patients tested. Hydronephrosis was present in 17 (68 %) patients; 8 (47 %) of 17 had bilateral hydronephrosis. Retroperitoneal mass biopsy was performed in 18 (69 %) patients. Two patients had idiopathic retroperitoneal fibrosis classifiable as IgG4-related disease. Therapy consisted of medications alone in 7 cases, surgical interventions alone in 7 cases, and a combination in 11 cases. One patient achieved remission with no treatment. Most patients treated medically received initial corticosteroids. Methotrexate (1 case), azathioprine (1 case), mycophenolate mofetil (1 case), and tamoxifen (5 cases) were used. No relapses occurred after a median 5-year follow-up. Two (8 %) patients died; five (19 %) developed cancer after diagnosis. In this series, we emphasize the importance of early diagnosis and therapy for overall favorable prognosis of idiopathic retroperitoneal fibrosis.
Similar content being viewed by others
References
Scheel PJ Jr, Feeley N (2013) Retroperitoneal fibrosis. Rheum Dis Clin N Am 39:365–381
Vaglio A, Salvarani C, Buzio C (2006) Retroperitoneal fibrosis. Lancet 367:241–251
Salvarani C, Pipitone N, Versari A, Vaglio A, Serafin D, Bajocchi G, Salvo D, Buzio C, Greco P, Boiardi L (2005) Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 53:298–303
van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL (2009) Iodiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 88:193–201
Scheel PJ Jr, Feeley N (2009) Retroperitoneal fibrosis; the clinical, laboratory, and radiographic presentation. Medicine (Baltimore) 88:202–207
Kermani TZ, Crowson CS, Achenbach SJ, Luthra HS (2011) Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc 86:297–303
Gómez García I, Sánchez Castaño A, Romero Molina M, Rubio Hidalgo E, García Betancourth N, Labra González R, Sampietro Crespo A, Álvarez Fernández F, Flores Herrero Á, Gómez Rodríguez A (2013) Retroperitoneal fibrosis: single-centre experience from 1992 to 2010, current status of knowledge and review of the international literature. Scand J Urol 47:370–377
Goldoni M, Bonini S, Urban ML, Palmisano A, De Palma G, Galletti E, Coggiola M, Buzio C, Mutti A, Vaglio A (2014) Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study. Ann Intern Med 161:181–188
Pipitone N, Vaglio A, Salvarani C (2012) Retroperitoneal fibrosis. Best Pract Res Clin Rheumatol 26:439–448
Parums DV, Brown DL, Mitchinson MJ (1990) Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 114:383–387
Vaglio A, Corradi D, Manenti L, Ferretti S, Garini G, Buzio C (2003) Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med 114:454–462
Stone JR (2011) Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr Opin Rheumatol 23:88–94
Pelkmans LG, Aarnoudse AJ, Hendriksz TR, van Bommel EF (2012) Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant 27:2819–2825
Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366:539–551
Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, Ferrozi F, Corradi D, Salvarani C, Buzio C (2011) Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 378:338–346
van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prenisone. Am J Kidney Dis 49:615–625
Marcolongo R, Tavolini IM, Laveder F, Busa M, Noventa F, Bassi P, Semenzato G (2004) Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 116:194–197
Financial support
None.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yachoui, R., Sehgal, R. & Carmichael, B. Idiopathic retroperitoneal fibrosis: clinicopathologic features and outcome analysis. Clin Rheumatol 35, 401–407 (2016). https://doi.org/10.1007/s10067-015-3022-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-015-3022-y